Latin American Developing Markets for Pharmaceuticals, 2006-2011

1. Executive Summary: Developing Markets for Pharmaceuticals, 2006-2011
2. The Global Pharmaceutical Industry Faces Significant Challenges – Will Expansion into Developing Markets Prove to Be the Answer?
2.1 The World Pharmaceutical Market Continues to Grow at a Moderate Rate
2.2 The Principal Markets Are the US, Japan and Leading EU Economies - But Leading Developing Nations Are Narrowing the Gap in Pharmaceutical Revenues
2.3 China is the Ninth Largest World Pharmaceutical Market
2.4 North America, Europe and Japan Continue to Dominate the World Pharmaceutical Market, But Sales in the Developing Markets Are Increasing More Rapidly
2.5 High Growth in the Developing Markets
2.6 China is a Most Exciting Prospect for the Pharmaceutical Industry
2.7 Latin America Exhibits Great Promise for Growth of Pharmaceutical Revenues
2.8 WTO Agreements Affect Pharmaceutical Developments In Emerging Markets
2.9 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
2.10 Pharmaceutical Companies Will Jostle Vigorously for Position in Developing Markets
2.11The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
2.12 Sales of Generic Products Continue to Encroach Upon the Market for Branded Drugs
2.13 Patent Protection Strategies Form a Cornerstone of Lifecycle Management
2.14 Is Innovation Declining in the Pharmaceutical Industry?
2.15 There Are Strong Forces Acting on Pharmaceutical Pricing In Leading Markets
2.15.1 The US Branded Market Faces Significant Challenges From Generics and Parallel Trade
2.15.2 Mandatory Price Reductions in Europe Continue to Harass the Pharmaceutical Industry
2.15.3 Governmental Price Controls Are an Established Part of the Japanese Pharmaceutical Market
2.15.4 It Is Possible That Mandatory Cost-Controls in Germany Will Serve As A Precedent For Wider Governmental Controlling of Prices
2.15.5 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
2.16 Maximising the Impact of Product Launches Yields Commercial Advantages
2.17 Strong Branding is Vital - Both in Established and Emerging Markets
2.18 Expansion Into Developing Countries Will Help to Reinvigorate The Pharmaceutical Industry from 2006-2011
3. Developing Pharmaceutical Markets in Latin America
3.1 Latin America Will Provide a Very Large and Fast Growing Market for Pharmaceutical Products from 2005 to 2011
3.2 Latin American Pharmaceutical Markets Are Driven By Several Important Factors
3.3 As In Other Developing Regions, Widespread Poverty Remains A Serious Limiting Factor
3.4 Growth in GDP Will Drive Growth in The Latin American Pharmaceutical Markets
3.5 Protection of IP and Other Regulatory Issues Will Remain Prominent in Latin America
3.5.1 Governmental Intervention Will Attempt to Widen Access to Medications
3.5.2 IP Issues Remain Contentious in Parts of Latin America
3.5.3 There are Also Concerns About Safety and Efficacy of Domestic Products
3.6 Significant Challenges Remain for the Public and Private Sectors in The Improvement of Healthcare in Latin America
3.7 The Pharmaceutical Market in Mexico
3.8 The Pharmaceutical Market in Brazil
3.9 The Pharmaceutical Market in Argentina
3.10 The Pharmaceutical Market in Venezuela
3.11 The Pharmaceutical Market in Puerto Rico
3.12 Overview of Developing Pharmaceutical Markets in Latin America
4. Conclusions
4.1 China Will Produce the Largest Revenues of All the Developing Pharmaceutical Markets As Well As the Highest Growth Rate
4.2 Overall Growth of the Leading Developing Markets from 2005-2011 Will Be More than Twice that of the Global Pharmaceutical Market
4.3 The Leading Developing Markets Combined Will Generate More Than a Sixth of Global Pharmaceutical Revenues in 2011
4.4 The Main Drivers of Developing Markets Will Be Increasing Prosperity and High Un-met Needs for Modern Treatments
4.5 The Main Restraint to Growth Will Be Continuing Poverty in the Developing World

List of Tables
Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
Table 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
Table 2.3 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2005
Table 2.4 How the Top 10 Markets Compared With The Rest of the World, 2005
Table 2.5 World Pharmaceutical Revenues ($bn) by Region, 2005
Table 2.6 Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005
Table 2.7 Combined Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005
Table 2.8 A SWOT Analysis for Developing Pharmaceutical Markets, 2006-2011
Table 2.9 The 10 Most Populous Countries – 2005 and 2030 Compared
Table 3.1 Revenues ($bn) for Leading Markets in Latin America, 2005-2011
Table 3.2 Pharmaceutical Revenues ($bn) for Mexico, 2005-2011
Table 3.3 Mexico: Fundamental Demographics and Healthcare Economics
Table 3.4 Pharmaceutical Revenues ($bn) for Brazil, 2005-2011
Table 3.5 Brazil: Fundamental Demographics and Healthcare Economics
Table 3.6 Pharmaceutical Revenues ($bn) for Argentina, 2005-2011
Table 3.7 Argentina: Fundamental Demographics and Healthcare Economics
Table 3.8 Pharmaceutical Revenues ($bn) for Venezuela, 2005-2011
Table 3.9 Venezuela: Fundamental Demographics and Healthcare Economics
Table 3.10 Pharmaceutical Revenues ($bn) for Puerto Rico, 2005-2011
Table 3.11 Puerto Rico: Fundamental Demographics and Healthcare Economics
Table 4.1 The Leading Developing Markets Ranked in Order of Potential Revenue Generation ($bn), 2011
Table 4.2 Developing Markets Ranked by Growth Rate (CAGR %), 2005-2011
Table 4.3 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
Table 4.4 Share (%) of the World Market by Developing Region, 2005-2011

List of Figures
Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
Figure 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011
Figure 2.3 World Pharmaceutical Revenues ($bn) by Region, 2005
Figure 2.4 World Market Share (%) by Region, 2005
Figure 2.5 Growth Rates (%) from Previous Year by Region, 2005
Figure 2.6 The Increasing Average Cost ($m) of NME Development, 1976-2005
Figure 3.1 Revenues ($bn) for Leading Markets in Latin America, 2005-2011
Figure 3.2 Combined Revenues ($bn) for Leading Markets in Latin America, 2005-2011
Figure 3.3 Growth Rates (% CAGR) for the Latin American Markets, 2005-2011
Figure 3.4 Pharmaceutical Revenues ($bn) for Mexico, 2005-2011
Figure 3.5 World Market Share (%) for Mexico – 2005 and 2011 Compared
Figure 3.6 Pharmaceutical Revenues ($bn) for Brazil, 2005-2011
Figure 3.7 World Market Share (%) for Brazil – 2005 and 2011 Compared
Figure 3.8 Pharmaceutical Revenues ($bn) for Argentina, 2005-2011
Figure 3.9 World Market Share (%) for Argentina – 2005 and 2011 Compared
Figure 3.10 Pharmaceutical Revenues ($bn) for Venezuela, 2005-2011
Figure 3.11 World Market Share (%) for Venezuela – 2005 and 2011 Compared
Figure 3.12 Pharmaceutical Revenues ($bn) for Puerto Rico, 2005-2011
Figure 3.13 World Market Share (%) for Puerto Rico – 2005 and 2011 Compared
Figure 4.1 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011
Figure 4.2 Revenues ($bn) for Leading Markets of Developing Regions Combined, 2005-2011
Figure 4.3 Share (%) of the World Market by Developing Region, 2005-2011
Figure 4.4 Share (%) of the World Market by Developing Regions Combined, 2005-2011